Stock Events

Tissue Regenix 

GBX71.1
30
-GBX0.4-0.56% Today

Statistics

Day High
72.7
Day Low
69.3
52W High
-
52W Low
-
Volume
41,835.46
Avg. Volume
-
Mkt Cap
50.46M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19MarExpected
Q1 2021
Q2 2021
Q1 2022
Q2 2022
Q4 2022
Q2 2023
Next
0
0.33
0.67
1
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TRX.LSE. It's not an investment recommendation.

About

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of bone graft substitutes and soft tissue in the United States and internationally. It operates in three segments: dCELL, BioRinse, and GBM-V. The company provides dCELL technology, a soft tissue decellularisation process that removes DNA and other cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductivity to stimulate and regenerate native bone growth. It also offers DermaPure, a decellularised dermal allograft for reinforcement, repair, and replacement of damaged or inadequate integumental tissue and other homologous uses of human integument; and SurgiPure XD, a decellularised porcine dermal reconstructive tissue matrix for the repair of hernias and body wall defects. In addition, it provides OrthoPure XT, a scaffold to replace the damaged tissue that will re-populate with the patient's own cells; ConCelltrate 100, a verified osteoinductive bone matrix; MatrixCellect 100, a demineralised bone matrix (DBM) for orthopaedic; Matrix IQ Dermis, a human-derived dermal graft, which is decellularised to remove cellular components and preserve the biological properties that promote revascularisation, repair, and augmentation of damaged tissue; and Matrix OI FlexIt, a thin pliable demineralised cortical allograft bone sheet. Further, the company offers DentalFix, a mineralized particulate allograft that offer osteoconductive properties of natural bone; Matrix OI 100 DBM for non-structural bone-grafting; Matrix OI Strips and Blocks, a stem cell containment human scaffold; AmnioWorks to optimise membrane defects; and sports medicine products. The company was incorporated in 2006 and is based in Garforth, the United Kingdom.
Show more...
CEO
Mr. Daniel Ray Lee
Employees
85
Country
GB
ISIN
GB00BNTXR104
WKN
000A1C0FE

Listings